[
    [
        {
            "time": "2020-08-05",
            "original_text": "恒瑞医药：SHR-1316注射液获国家药监局临床试验批",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "SHR-1316",
                    "临床试验",
                    "国家药监局"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "恒瑞医药：SHR-1316注射液获国家药监局临床试验批",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-08-05",
            "original_text": "北向资金8月5日成交活跃股名单抢先看",
            "features": {
                "keywords": [
                    "北向资金",
                    "成交活跃",
                    "8月5日"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北向资金8月5日成交活跃股名单抢先看",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-08-05",
            "original_text": "疫情下差旅费仍达4.46亿？恒瑞医药上半年营收利润增速创十年新低，盈利能力下降",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "疫情",
                    "差旅费",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "疫情下差旅费仍达4.46亿？恒瑞医药上半年营收利润增速创十年新低，盈利能力下降",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-08-05",
            "original_text": "国信证券医药业8月投资策略：新冠疫情肆虐，疫苗与检测主线持续",
            "features": {
                "keywords": [
                    "国信证券",
                    "医药",
                    "新冠疫苗",
                    "检测"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "国信证券医药业8月投资策略：新冠疫情肆虐，疫苗与检测主线持续",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-05",
            "original_text": "跟着牛市旗手去炒股！券商资管10大重仓股曝光",
            "features": {
                "keywords": [
                    "牛市",
                    "券商资管",
                    "重仓股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "跟着牛市旗手去炒股！券商资管10大重仓股曝光",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]